Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.

Abstract

In this preliminary study, the Adnatest® detected CTCs in a considerable proportion of patients with castration-resistant PC. First data on certain markers (EGFR and aldehyd dehydrogenase 1) encourage future studies investigating transcripts predicting treatment response.